natgillin/translations-raw huggingface dataset:
The process of claim 1, wherein the contaminants comprise at least one component selected from the group consisting of stones, silica-containing particles, sand, metal objects. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 14, gdje onečišćenja sadrže najmanje jednu komponentu odabranu iz grupe koja se sastoji od kamenja, čestica koje sadrže silicij-dioksid, pijeska, metalnih predmeta.
An antibody polypeptide with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises 
Polipeptid antitijela sa specifičnošću vezanja za humani kallikrein-2 (hK2), pri čemu polipeptid antitijela obuhvaća
A pharmaceutical composition comprising an antibody polypeptide according to claim 1 and a pharmaceutically acceptable excipient, diluent or carrier. 
Farmaceutski sastav koji obuhvaća polipeptid antitijela prema bilo kojim Zahtjevima 1 do 10 i farmaceutski prihvatljiva pomoćna tvar, razrjeđivač ili nosač.
preparation of 2,4,5-trifluorophenylacetic acid of formula (II) or salt thereof: by direct conversion of the compound of (III): to the compound of formula (II), wherein said direct conversion is carried out by reduction reaction; 
priprava 2,4,5-trifluorfeniloctene kiseline formule (II) ili njezine soli: izravnim prevođenjem spoja formule (III): u spoj formule (II), gdje se navedeno izravno prevođenje provodi reakcijom redukcije;
conversion of 2,4,5-trifluorophenylacetic acid of formula (II) obtained in the step A) to Sitagliptin of formula (I) or salt thereof. 
prevođenja 2,4,5-trifluorfeniloctene kiseline formule (II) dobivene u koraku A) u sitagliptin formule (I) ili njegovu sol.
Process according to claim 1, wherein the step B) is carried out by means of the following steps: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se korak B) provodi uz pomoć sljedećih koraka:
conversion of 2,4,5-trifluorophenylacetic acid of formula (II) obtained in the step A) to Ketoamide of formula (IV): 
prevođenja 2,4,5-trifluorfeniloctene kiseline formule (II) dobivene u koraku A) u ketoamid formule (IV):;
amination reaction of Ketoamide of formula (IV) produced in the step C) to give Enamine Amide of formula (V): 
reakcije aminiranja ketoamida formule (IV) proizvedenog u koraku C) kako bi se dobilo enaminski amid formule (V):;
enzymatic conversion of Ketoamide of formula (IV), obtained in the step C), to Sitagliptin of formula (I): 
enzimskog prevođenja ketoamida formule (IV), dobivenog u koraku C), u sitagliptin formule (I): .
conversion of the compound of formula (VII) prepared in the step a) to the compound of formula (III): 
; prevođenja spoja formule (VII) pripravljenog u koraku a) u spoj formule (III):
Process according to the claim 5, wherein the iodide catalyst is sodium iodide. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što je jodidni katalizator natrijev jodid.
Process according to the claim 8, wherein the phosphorus and/or sulphurous reductant is phosphorous acid. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je fosforni i/ili sumporni reducens fosforasta kiselina.
Process according to the claim 10, wherein the acid solvent or an aqueous acid mixture thereof is selected in the group comprising of hydrobromic acid, acetic acid, methansulphonic acid. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se kiselinsko otapalo ili njegovu vodeno kiselinsku smjesu bira iz skupine koju čine bromovodična kiselina, octena kiselina, metansulfonska kiselina.
Process according to anyone of the claims from 1 to 11, wherein the reduction reaction of step A) is carried out in presence of iodide catalyst and with a phosphorus and/or sulphurous reductant and is carried out in an acid solvent or an aqueous acid mixture thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 1 do 11, naznačen time što se reakciju redukcije u koraku A) provodi u prisutnosti jodidnog katalizatora i uz fosforni i/ili sumporni reducens i provodi se u kiselinskom otapalu ili njegovoj vodeno kiselinskoj smjesi.
Process according to the claim 12, wherein the acid solvent or an aqueous acid mixture thereof is selected in the group comprising of hydrobromic acid, acetic acid and methansulphonic acid. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se kiselinsko otapalo ili njegovu vodeno kiselinsku smjesu bira iz skupine koju čine bromovodična kiselina, octena kiselina i metansulfonska kiselina.
Process according to the claim 12, wherein the iodide catalyst is sodium iodide, the phosphorus and/or sulphurous reductant is phosphorous acid, and the acid solvent or an aqueous acid mixture thereof is selected in the group comprising of hydrobromic acid, acetic acid and methansulphonic acid. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što je jodidni katalizator natrijev jodid, fosforni i/ili sumporni reducens je fosforasta kiselina, kiselinsko otapalo ili njegovu vodeno kiselinsku smjesu se bira iz skupine koju čine bromovodična kiselina, octena kiselina i metansulfonska kiselina.
Process according to the claims 14, wherein the acid solvent or an aqueous acid mixture thereof is methanesulphonic acid. 
Postupak u skladu s patentnih zahtjeva 14, naznačen time što je kiselinsko otapalo ili njegova vodeno kiselinska smjesa metanesulfonska kiselina.
The actuation device (100) of claim 1 or 2, wherein said ribs (11) of the section have an "L"-shape in cross-section and are disposed in opposite position in such a way to form a "C"-shaped housing. 
Uređaj za pokretanje (100) prema zahtjevu 1 ili 2, naznačen time, da spomenuta rebra (11) presjeka imaju poprečni presjek "L" oblika i raspoređena su u suprotnom položaju na takav način da tvore kućište oblika "C" .
Shutter assembly (G) comprising: 
Sklop rolete (G) sadrži:
at least one wing comprising a frame composed of two uprights and two crosspieces, and a plurality of slats (5) movably and adjustably mounted with respect to said frame; said slats being provided with fastening means (M1) disposed at the two ends of the slats (5); 
barem jedno krilo koje sadrži okvir koji se sastoji od dva stupa i dva poprečnog nosača, te više letvica (5) koje su pomično i podesivo postavljene u odnosu na navedeni okvir; spomenute letvice su opremljene sredstvima za pričvršćivanje (M1) postavljenim na dva kraja letvica (5);
said fastening means (M2) of the flange comprise a housing (20) disposed in a central position of the flange (2) and consisting in a non-circular hole, and 
spomenuto sredstvo za pričvršćivanje (M2) prirubnice obuhvaća kućište (20) smješteno u središnjem položaju prirubnice (2) i koje se sastoji od ne-kružne rupe, i
The seasonal thermal energy storage system for cold and heat supply of claim 1, characterized in that the solar collector (2) employs a trough heat concentrating device.. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 1, naznačen time što solarni kolektor (2) koristi prolazni uređaj za koncentriranje topline.
The seasonal thermal energy storage system for cold and heat supply of claim 2, characterized in that the user terminal (5) is a low temperature ground radiant panel. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 2, naznačen time što korisnički terminal (5) je nisko temperaturna podna ploča za zračenje.
The seasonal thermal energy storage system for cold and heat supply of claim 4, characterized in that temperature sensors and liquid level detectors are disposed in the heat source storage pond (11), the cold source storage pond (12), the hot water supply pool (41), and the cold water supply pool (42); all the water pumps are provided with a magnetic valve; an intelligent control unit is connected to the temperature sensors, the liquid level detectors, and the magnetic valve for controlling the opening/closing of the magnetic valve according to signals gathered by the temperature sensors and the liquid level detectors whereby opening/closing corresponding water pumps. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 4, naznačen time što su temperaturni senzori i detektori razine tekućine smješteni u bazenu za pohranjivanje izvora topline (11), bazenu za pohranjivanje rashladnog izvora (12), bazenu za opskrbu toplom vodom (41), te bazenu za opskrbu hladnom vodom (42); sve vodene crpke imaju magnetski ventil; inteligentna upravljačka jedinica spojena je na temperaturne senzore, detektore razine tekućine, te magnetski ventil za kontrolu otvaranja/zatvaranja magnetskog ventila prema signalima koje prikupljaju temperaturni senzori i detektori razine tekućine pri čemu se otvaraju/zatvaraju odgovarajuće vodene crpke.
The seasonal thermal energy storage system for cold and heat supply of claim 9, characterized in that the solar collector is replaced by an industrial waste heat supply device. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 5, naznačen time što je solarni kolektor (2) zamijenjen uređajem za isporuku industrijske otpadne topline.
is an unsubstituted C3-C8cycloalkyl, an unsubstituted 5-6 membered heterocycloalkyl with 1-2 heteroatoms independently selected from N or O or a C3-C8cycloalkyl substituted with 1-3 substituents independently selected from C1-C6alkyl; each R6 is independently selected from -NHC(O)OR4, -OR4 and -(CR92)nOR4; 
je nesupstituirani C3-C8cikloalkil, nesupstituirani 5-6-eročlani heterocikloalkil s 1-2 heteroatoma koji su neovisno odabrani od N ili O ili C3-C8cikloalkil supstituiran s 1-3 supstituenta koji su neovisno odabrani od C1-C6alkila; svaki R6 je neovisno odabran iz niza koji čine -NHC(O)OR4, -OR4 i -(CR92)nOR4;
is cyclopropyl substituted with 1 or 2 F, or 
je ciklopropil supstituiran s 1 ili 2 F, ili
A pharmaceutical composition comprising a therapeutically effective amount a compound of any one of claims 1 to 24 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 24 i farmaceutski prihvatljiv nosač.
A compound of any one of claims 1 to 24 for use in treating a disease mediated by a kinase selected from c-kit, PDGFRa, and PDGFRβ, wherein the disease is a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) or primary pulmonary hypertension (PPH). 
Spoj prema bilo kojem od zahtjeva 1 do 24, naznačen time, što je za uporabu u liječenju bolesti posredovane s kinazom koja je odabrana od c-kit, PDGFRa, i PDGFRβ, pri čemu bolest je respiratorna bolest, upalni poremećaj, sindrom iritabilnog crijeva (IBS), upalna bolest crijeva (IBD), autoimuni poremećaj, metabolička bolest, fibrozna bolest, dermatološka bolest, plućna arterijska hipertenzija (PAH) ili primarna plućna hipertenzija (PPH).
The compound for use according to claim 27, wherein the disease is asthma, allergic rhinitis, pulmonary arterial hypertension (PAH), pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), uticaria, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, melanoma, a gastrointestinal stromal tumor, a mast cell tumor, mastocytosis, anaphylactic syndrome, dermatosis, Crohn's disease, type I diabetes or type II diabetes. 
Spoj za uporabu prema zahtjevu 27, naznačen time, što bolest je astma, alergijski rinitis, plućna arterijska hipertenzija (PAH), plućna fibroza, fibroza jetre, kardijalna fibroza, sklerodermija, sindrom iritabilnog crijeva (IBS), upalna bolest crijeva (IBD), urtikarija, atopijski dermatitis, alergijski kontaktni dermatitis, reumatoidni artritis, multipla skleroza, melanom, gastrointestinalni stromalni tumor, tumor mastocita, mastocitoza, anafilaktički sindrom, dermatoza, Crohnova bolest, dijabetes tipa I ili dijabetes tipa II.
A combination of a compound of Formula (I) or Formula (II), of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, with an immunoglobulin (Ig), gamma globulin, Ig preparation or an antagonist or antibody modulating Ig function selected from anti-IgE, in particular omalizumab. 
Kombinacija, naznačena time, što je od spoja s Formulom (I) ili Formulom (II), prema bilo kojem od zahtjeva 1 do 24, ili njegove farmaceutski prihvatljive soli, s imunoglobulinom (Ig), gama globulinom, Ig pripravkom ili antagonistom ili protutijelom koje modulira Ig funkciju odabranom od anti-IgE, naročito s omalizumabom.
An adhesive composition, curable via free radical polymerisation, the composition comprising the following, based on the total weight of components (A), (B), (C) and (D): 
Sastav ljepila, naznačen time, da se može očvrsnuti putem polimerizacije slobodnih radikala, pri čemu sastav, na bazi ukupne mase sastojaka (A), (B), (C) i (D), obuhvaća sljedeće:
An adhesive composition according to claim 1, wherein a urethane (meth)acrylate oligomer (D) is derived from: 
Sastav ljepila prema zahtjevu 1, naznačen time, da je oligomer uretan-(met)akrilata (D) izveden iz sljedećih:
a di- or higher isocyanate having at least two isocyanate groups; 
diizocijanata ili višeg izocijanata koji ima najmanje dvije izocijanatne skupine;
a chain-extending reagent which has at least two groups selected from hydroxyl and/or amino groups, each capable of reaction with an isocyanate group of (i); 
reagensa produljivanja lanca koji ima najmanje dvije skupine odabrane od hidroksil-skupina i/ili amino-skupina, od kojih je svaka sposobna za reakciju s jednom izocijanatnom skupinom iz (i);
An adhesive composition according to claim 2, wherein the diisocyanate is selected from isophorone diisocyanate and 2,4-toluene diisocyanate. 
Sastav ljepila prema zahtjevu 2, naznačen time, da je diizocijanat odabran od izoforon-diizocijanata i 2,4-toluen-diizocijanata.
An adhesive composition according to claim 2 or 3, wherein the chain-extending reagent (ii) includes at least three groups capable of reaction with an isocyanate group of (i). 
Sastav ljepila prema zahtjevu 2 ili 3, naznačen time, da reagens produljivanja lanca (ii) uključuje najmanje tri skupine koje su sposobne za reakciju s jednom izocijanatnom skupinom iz (i).
An adhesive composition according to any one of claims 2 to 4, wherein the chain-extending reagent (ii) is a polyester polyol or polyether polyol. 
Sastav ljepila prema bilo kojem od zahtjeva 2 do 4, naznačen time, da reagens produljivanja lanca (ii) je poliester-poliol ili polieter-poliol.
An adhesive composition according to claim 5, wherein the chain-extending reagent (ii) is a polyester polyol obtainable by polymerisation of a lactone such as a caprolactone selected from γ-caprolactone, δ-caprolactone, ε-caprolactone, and preferably ε-caprolactone. 
Sastav ljepila prema zahtjevu 5, naznačen time, da reagens produljivanja lanca (ii) je poliester-poliol koji se može dobiti pomoću polimerizacije laktona kao što je primjerice kaprolakton odabran od γ-kaprolaktona, δ-kaprolaktona, ε-kaprolaktona, dok je poželjno odabran od ε-kaprolaktona.
An adhesive composition according to claim 6, wherein the chain-extending reagent (ii) is derived from ε-caprolactone and a tri- or higher functional alcohol such as a sugar alcohol, preferably sorbitol. 
Sastav ljepila prema zahtjevu 6, naznačen time, da je reagens produljivanja lanca (ii) izveden iz ε-kaprolaktona i tro- ili višefunkcionalnog alkohola kao što je primjerice šećerni alkohol, poželjno sorbitol.
An adhesive composition according to claim 5, wherein the chain-extending reagent (ii) is a polyether polyol selected from ethoxylated and propoxylated derivatives of tri- or higher functional polyols, preferably tri- or tetra functional polyols. 
Sastav ljepila prema zahtjevu 5, naznačen time, da reagens produljivanja lanca (ii) je polieter-poliol odabran od etoksiliranih i propoksiliranih derivata od trostruko ili višefunkcionalnih poliola, poželjno trofunkcionalnih ili tetrafunkcionalnih poliola.
An adhesive composition according to any one of claim 2 to 9, wherein (iii) is a hydroxyl(meth)acrylate, preferably selected from a polyethylene glycol methacrylate and polypropylene glycol methacrylate. 
Sastav ljepila prema bilo kojem od zahtjeva 2 do 9, naznačen time, da (iii) je hidroksil(met)akrilat, poželjno odabran od polietilen-glikol-metakrilata i polipropilen-glikol-metakrilata.
a polyol selected from ethoxylated and propoxylated derivatives of trimethylol propane and ethoxylated and propoxylated derivatives of pentaerythritol; and 
poliola odabranog od etoksiliranih i propoksiliranih derivata od trimetilol-propana te etoksiliranih i propoksiliranih derivata od pentaeritritola; i
An adhesive composition according to any preceding claim, wherein the chlorinated elastomeric polymer (B) is selected from chlorinated polyethylenes and polychloroprenes and is preferably a polychloroprene. 
Sastav ljepila prema bilo kojem od prethodnih zahtjeva, naznačen time, da je klorirani elastomerni polimer (B) odabran od kloriranih polietilena i polikloroprena, te je to poželjno polikloropren.
a component capable of initiating free radical polymerisation of components (A) to (D): and/or 
sastojak koji je sposoban za pokretanje polimerizacije slobodnih radikala za sastojke od (A) do (D); i/ili
an acid-functional ethylenically unsaturated monomer; 
kiselinsko-funkcionalni etilenski nezasićeni monomer;
a chelating agent; a wax; and 
vosak; i sredstvo za kontrolu viskoziteta.
A two part system for an adhesive which comprises first and second parts, which, in combination contain components (A), (B), (C) and (D) as defined in any one of claims 1 to 11, together with 
Dvokomponentni sustav za ljepilo, naznačen time, da obuhvaća prvu i drugu komponentu, koje u kombinaciji sadrže sastojke (A), (B), (C) i (D) kako su definirani u bilo kojem od zahtjeva 1 do 15, zajedno sa:
a component capable of initiating free radical polymerisation of components (A) to (D); and 
sastojkom koji je sposoban za pokretanje polimerizacije slobodnih radikala za sastojke od (A) do (D); i
a component capable of promoting the polymerisation, provided that (I) and (P) are contained in different respective parts of the two part system. 
sastojkom koji je sposoban za unapređivanje polimerizacije slobodnih radikala, pod uvjetom da (I) i (P) budu odgovarajuće sadržani u različitim komponentama od dvokomponentnog sustava.
A urethane (meth)acrylate oligomer suitable for use in an adhesive composition as claimed in claim 1, wherein the urethane (meth)acrylate is derived from: 
Oligomer uretan-(met)akrilata, naznačen time, da je prikladan za uporabu u sastavu ljepila prema zahtjevu 1, pri čemu je oligomer uretan-(met)akrilata izveden iz sljedećih:
a diisocyanate having two isocyanate groups which differ in reactivity; 
diizocijanata koji ima najmanje dvije izocijanatne skupine različitog reaktiviteta;
a chain-extending reagent which is a polyether polyol selected from ethoxylated and propoxylated derivatives of tri- and tetra- functional polyols; and 
reagensa produljivanja lanca koji je polieter-poliol odabran od etoksiliranih i propoksiliranih derivata od trofunkcionalnih i tetrafunkcionalnih poliola;
A urethane (meth)acrylate oligomer according to claim 17, which is derived from a chain-extending reagent (ii) which is selected from ethoxylated and propoxylated derivatives of trimethylol propane and ethoxylated and propoxylated derivatives of pentaerythritol. 
Oligomer uretan-(met)akrilata prema zahtjevu 17, naznačen time, da je izveden iz reagensa produljivanja lanca (ii) koji je odabran od etoksiliranih i propoksiliranih derivata od trimetilol-propana te etoksiliranih i propoksiliranih derivata pentaeritritola.
core-shell impact modifier. 
modifikator udarca ljuska-jezgra.
A composition comprising a bacterial strain of the species Blautia hydrogenotrophica, for use in a method of treating or preventing visceral hypersensitivity. 
Sastav koja obuhvaća bakterijski soj vrste Blautia hydrogenotrophica, za upotrebu u postupku liječenja ili prevenciji visceralne hipersenzitivnosti.
The composition for use of claim 1, wherein the visceral hypersensitivity is associated with IBS, Crohn's disease, ulcerative colitis, functional dyspepsia or infantile colic. 
Sastav za upotrebu prema zahtjevu 1, gdje je visceralna hipersenzitivnost povezana sa IBS-om, Chronovom bolesti, ulceroznim kolitisom, funkcionalnom dispepsijom ili dojenačkim kolikama.
The composition for use of claim 2, wherein the visceral hypersensitivity is associated with IBS, Crohn's disease, ulcerative colitis or functional dyspepsia. 
Sastav za upotrebu prema zahtjevu 2, gdje je visceralna hipersenzitivnost povezana sa IBS-om, Chronovom bolesti, ulceroznim kolitisom ili funkcionalnom dispepsijom.
The composition for use of any preceding claim, wherein the composition is for use in: 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je sastav za upotrebu u:
The composition for use of claims 1-6, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia hydrogenotrophica. 
Sastav za upotrebu prema zahtjevima 1-6, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% identična sa 16s rRNK sekvencom bakterijskog soja Blautia hydrogenotrophica.
The composition for use of claim 7, wherein the bacterial strain has a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5 or which has the 16s rRNA sequence of SEQ ID NO:5. 
Sastav za upotrebu prema zahtjevu 7, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 97%, 98%, 99%, 99.5% ili 99.9% identična sa SEQ ID NO:5 ili koja ima 16s rRNK sekvencu SEQ ID NO:5.
The composition for use of claim 1, wherein the composition comprises a bacterial strain of the species Blautia hydrogenotrophica, for use in: 
Sastav za upotrebu prema zahtjevu 1, gdje sastav obuhvaća bakterijski soj vrste Blautia hydrogenotrophica, za upotrebu u:
The composition for use of any preceding claim, wherein the composition is for oral administration. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je sastav za oralnu primjenu.
The composition for use of any preceding claim, wherein the composition comprises a 10 single strain of the species Blautia hydrogenotrophica. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu sastav obuhvaća 10 pojedinačnih sojeva vrste Blautia hydrogenotrophica.
is lower alkyl, wherein lower alkyl means an alkyl group having from 1 to 7 carbon atoms; 
je niži alkil, pri čemu niži alkil znači alkilna skupina s 1 do 7 atoma ugljika;
or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
ili njegova farmaceutski prihvatljiva sol ili kiselinska adicijska sol, njegova racemična smjesa ili njezini odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
A compound of formula IA according to claim 1, wherein is lower alkyl; is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; 
Spoj formule IA prema patentnom zahtjevu 1, naznačen time, da je niži alkil; je fenil ili piridinil, gdje atom dušika u piridinilskoj skupini može zauzimati različite položaje;
A compound of formula IB according to claim 1, wherein is lower alkyl; is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; 
Spoj formule IB prema patentnom zahtjevu 1, naznačen time, da je niži alkil; je fenil ili piridinil, gdje atom dušika u piridinilskoj skupini može zauzimati različite položaje;
is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; 
R² je fenil ili piridinil, gdje atom dušika u piridinilskoj skupini može zauzimati različite položaje;
is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; 
je fenil ili piridinil, gdje atom dušika u piridinilskoj skupini može zauzimati različite položaje;